articleScience Translational MedicineAug 26, 2015Closed access

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

LRLaura R. SaundersAJAlexander J. BankovichWAWade AndersonMAMonette AujaySBSheila Bheddah

ChemoCentryx (United States) · AstraZeneca (Poland) · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

The high-grade pulmonary neuroendocrine tumors, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), remain among the most deadly malignancies. Therapies that effectively target and kill tumor-initiating cells (TICs) in these cancers should translate to improved patient survival. Patient-derived xenograft (PDX) tumors serve as excellent models to study tumor biology and characterize TICs. Increased expression of delta-like 3 (DLL3) was discovered in SCLC and LCNEC PDX tumors and confirmed in primary SCLC and LCNEC tumors. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues. A DLL3-targeted antibody-drug conjugate (ADC), SC16LD6.5, comprised of a…

Citation impact

575
total citations
FWCI
22.08
Percentile
100%
References
53
Citations per year

Authors

33

Topics & keywords

Topics
Keywords
  • In vivo
  • Antibody-drug conjugate
  • Conjugate
  • Antibody
  • Drug
  • Medicine
  • Pharmacology
  • Monoclonal antibody
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding